MAPT haplotype diversity in multiple system atrophy
| Autor: | Steven G. Younkin, Ronald L. Walton, Ronald C. Petersen, William P. Cheshire, Neill R. Graff-Radford, Kotaro Ogaki, Zbigniew K. Wszolek, Dennis W. Dickson, Michael G. Heckman, Phillip A. Low, Ryan J. Uitti, Elizabeth A. Coon, Oswaldo Lorenzo-Betancor, Shinsuke Fujioka, Alexandra I. Soto-Ortolaza, Wolfgang Singer, Owen A. Ross, Paola Sandroni, Catherine Labbé, Shunsuke Koga, Melissa E. Murray, Bradley F. Boeve, Jay A. van Gerpen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Risk 0301 basic medicine medicine.medical_specialty Pathology Genotype tau Proteins Single-nucleotide polymorphism Disease Polymorphism Single Nucleotide Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Atrophy stomatognathic system Internal medicine parasitic diseases mental disorders medicine Humans Genetic Predisposition to Disease Aged Aged 80 and over business.industry Haplotype Significant difference Parkinson Disease Progressive neurodegenerative disorder Middle Aged Multiple System Atrophy medicine.disease LRRK2 nervous system diseases 030104 developmental biology Haplotypes nervous system Neurology alpha-Synuclein Female Neurology (clinical) Geriatrics and Gerontology business 030217 neurology & neurosurgery |
| Zdroj: | Parkinsonism & Related Disorders. 30:40-45 |
| ISSN: | 1353-8020 |
| DOI: | 10.1016/j.parkreldis.2016.06.010 |
| Popis: | Introduction Multiple system atrophy (MSA) is a rare progressive neurodegenerative disorder. MSA was originally considered exclusively sporadic but reports of association with genes such as SNCA, COQ2 and LRRK2 have demonstrated that there is a genetic contribution to the disease. MAPT has been associated with several neurodegenerative diseases and we previously reported a protective association of the MAPT H2 haplotype with MSA in 61 pathologically confirmed cases. Methods In the present study, we assessed the full MAPT haplotype diversity in MSA patients using six MAPT tagging SNPs. We genotyped a total of 127 pathologically confirmed MSA cases, 86 patients with clinically diagnosed MSA and 1312 controls. Results We identified four significant association signals in our pathologically confirmed cases, two from the protective haplotypes H2 (MSA:16.2%, Controls:22.7%, p = 0.024) and H1E (MSA:3.0%, Controls:9.0%, p = 0.014), and two from the rare risk haplotypes H1x (MSA:3.7%, Controls:1.3%, p = 0.030) and H1J (MSA:3.0%, Controls:0.9%, p = 0.021). We evaluated the association of MSA subtypes with the common protective H2 haplotype and found a significant difference with controls for MSA patients with some degree of MSA-C (MSA-C or MSA-mixed), for whom H2 occurred in only 8.6% of patients in our pathologically confirmed series (P Conclusions Our findings provide further evidence that MAPT variation is associated with risk of MSA. Interestingly, our results suggest a greater effect size in the MSA-C compared to MSA-P for H2. Additional genetic studies in larger pathologically confirmed MSA series and meta-analytic studies will be needed to fully assess the role of MAPT and other genes in MSA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect